
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Galibra Neuroscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Apertura Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners
Details : Galibra Neuroscience and Emugen Therapeutics will utilize Apertura's human transferrin receptor 1 capsid (TfR1 CapX) for their central nervous system (CNS) programs.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
August 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Galibra Neuroscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : RSRT
Deal Size : Undisclosed
Deal Type : Collaboration
Apertura and Rett Trust Partner on TfR1-AAV Gene Therapy for Rett Syndrome
Details : The collaboration aims to advance the innovative genetic medicine, which is being evaluated in preclinical clinical trial studies for the treatment of Rett Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 30, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : RSRT
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Deerfield Management Company
Deal Size : $67.0 million
Deal Type : Series A Financing
Details : The two technology platforms have unique capabilities to simultaneously engineer AAV capsids to exhibit enhanced cellular tropism, evasion of pre-existing immunity, while maintaining and potentially improving manufacturability.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 26, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Deerfield Management Company
Deal Size : $67.0 million
Deal Type : Series A Financing

Contact Us!